Karyopharm 2025 Q3 Earnings Revenue Surges 13.6% Despite Widening Net Loss

, surpassing expectations, . , . .

Revenue

Product revenue, net, , . .

<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-qwen_generated_1762252933139.jpg.png" style="max-width:100%;">

Earnings/Net Income

, , . Despite a marginal EPS improvement, the broader financial challenges persist, .

Post-Earnings Price Action Review

, . The mixed performance reflects investor skepticism about near-term profitability despite clinical and financial progress.

CEO Commentary

highlighted the completion of the Phase III SENTRY trial for myelofibrosis and $100 million in financing, . He emphasized XPOVIO’s growth and strategic focus on advancing SENTRY, expanding the XPOVIO franchise, and maintaining financial discipline.

Guidance

Karyopharm reaffirmed 2025 total revenue guidance of $140–155 million and U.S. . , .

Additional News

Karyopharm completed enrollment in the Phase III SENTRY trial for myelofibrosis, positioning selinexor plus ruxolitinib as a potential all-oral treatment. , extending liquidity. Additionally, , . , with regulatory and commercial outcomes hinging on these results.